@prefix dcterms: . @prefix ns1: . @prefix this: . @prefix sub: . @prefix schema: . @prefix np: . @prefix rdf: . @prefix nt: . @prefix xsd: . @prefix rdfs: . @prefix orcid: . @prefix bl: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { bl:category bl:Disease . sub:association rdf:object ; rdf:predicate bl:treats; rdf:subject ; a rdf:Statement; rdfs:label "dactinomycin for injection is an actinomycin indicated for the treatment of 1 1 1 2 1 3 1 4 1 5 1 6 dactinomycin for injection is indicated for the treatment of adult and pediatric patients with wilms tumor as part of a multi phase combination chemotherapy regimen dactinomycin for injection is indicated for the treatment of adult and pediatric patients with rhabdomyosarcoma as part of a multi phase combination chemotherapy regimen dactinomycin for injection is indicated for the treatment of adult and pediatric patients with ewing sarcoma as part of a multi phase combination chemotherapy regimen dactinomycin for injection is indicated for the treatment of adult and pediatric patients with metastatic nonseminomatous testicular cancer as part of a multi phase combination chemotherapy regimen dactinomycin for injection is indicated for the treatment of post menarchal patients with gestational trophoblastic neoplasia as a single agent or as part of a combination chemotherapy regimen dactinomycin for injection is indicated for the treatment of adult patients with locally recurrent or locoregional solid malignancies as a component of palliative or adjunctive regional perfusion"; bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation; bl:provided_by ; bl:relation schema:TreatmentIndication . bl:category bl:Drug . } sub:provenance { sub:assertion ns1:wasAttributedTo orcid:0000-0002-1468-3557 . } sub:pubinfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"; npx:hasSignature "IrVnfsuN9YBtm6HDj0SB7+Qb4LfYTtnl9DrIoTM+qmOAGlYa5g8QFnnndFinsL10inhf4crD2JPvdy5jGFFK8vOEGotI8H1f6/x+fjiQTs/6usyh8nuCWiFcQcXpZn6Xs5J5Oj8EYcPKu7vmxEd+Bvwnr2xb6VbaZzM8pvZPqeo="; npx:hasSignatureTarget this: . this: dcterms:created "2021-07-03T13:02:43.973+02:00"^^xsd:dateTime; dcterms:creator orcid:0000-0002-1468-3557; nt:wasCreatedFromProvenanceTemplate ; nt:wasCreatedFromPubinfoTemplate ; nt:wasCreatedFromTemplate . }